New drug duo targets tough pancreatic cancer
NCT ID NCT04132505
Summary
This early-stage trial is testing a combination of two oral drugs, binimetinib and hydroxychloroquine, for people with advanced pancreatic cancer that has a specific genetic change (KRAS mutation). The main goal is to find the safest and most effective dose of hydroxychloroquine to use with binimetinib. Researchers hope this combination will work better than binimetinib alone to stop or slow the growth of cancer that has spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.